GB202014114D0 - Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid - Google Patents

Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Info

Publication number
GB202014114D0
GB202014114D0 GBGB2014114.9A GB202014114A GB202014114D0 GB 202014114 D0 GB202014114 D0 GB 202014114D0 GB 202014114 A GB202014114 A GB 202014114A GB 202014114 D0 GB202014114 D0 GB 202014114D0
Authority
GB
United Kingdom
Prior art keywords
beta
patients undergoing
undergoing treatment
copd patients
systemic corticosteroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2014114.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synairgen Research Ltd
Original Assignee
Synairgen Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synairgen Research Ltd filed Critical Synairgen Research Ltd
Priority to GBGB2014114.9A priority Critical patent/GB202014114D0/en
Publication of GB202014114D0 publication Critical patent/GB202014114D0/en
Priority to KR1020237011584A priority patent/KR20230066037A/ko
Priority to US18/024,648 priority patent/US20230241177A1/en
Priority to JP2023515363A priority patent/JP7877300B2/ja
Priority to CN202180061630.8A priority patent/CN116249545A/zh
Priority to EP21777826.5A priority patent/EP4210728A1/en
Priority to PCT/GB2021/052302 priority patent/WO2022053792A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GBGB2014114.9A 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid Ceased GB202014114D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
KR1020237011584A KR20230066037A (ko) 2020-09-08 2021-09-07 전신성 코르티코스테로이드 치료받는 copd 환자에서 바이러스에 의한 악화를 치료하기 위한 흡입형 인터페론 베타의 용도
US18/024,648 US20230241177A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
JP2023515363A JP7877300B2 (ja) 2020-09-08 2021-09-07 全身性コルチコステロイドによる治療を受けているcopd患者におけるウイルス誘導性増悪を治療するための吸入インターフェロン-ベータの使用
CN202180061630.8A CN116249545A (zh) 2020-09-08 2021-09-07 在接受全身型皮质类固醇治疗的COPD患者中使用吸入型干扰素-β治疗病毒诱导的恶化
EP21777826.5A EP4210728A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
PCT/GB2021/052302 WO2022053792A1 (en) 2020-09-08 2021-09-07 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2014114.9A GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Publications (1)

Publication Number Publication Date
GB202014114D0 true GB202014114D0 (en) 2020-10-21

Family

ID=72841287

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2014114.9A Ceased GB202014114D0 (en) 2020-09-08 2020-09-08 Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid

Country Status (7)

Country Link
US (1) US20230241177A1 (cg-RX-API-DMAC7.html)
EP (1) EP4210728A1 (cg-RX-API-DMAC7.html)
JP (1) JP7877300B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230066037A (cg-RX-API-DMAC7.html)
CN (1) CN116249545A (cg-RX-API-DMAC7.html)
GB (1) GB202014114D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022053792A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
GB0405634D0 (en) * 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
WO2015157955A1 (en) * 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
GB201820659D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy

Also Published As

Publication number Publication date
EP4210728A1 (en) 2023-07-19
US20230241177A1 (en) 2023-08-03
JP7877300B2 (ja) 2026-06-22
JP2023540591A (ja) 2023-09-25
WO2022053792A1 (en) 2022-03-17
KR20230066037A (ko) 2023-05-12
CN116249545A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
Desmet et al. Nanomedicines and gene therapy for the delivery of growth factors to improve perfusion and oxygenation in wound healing
IL299167A (en) Compositions and methods for treating patients with gene therapy
BR112015024869A8 (pt) uso de um agente terapêutico e/ou de diôxido de carbono para tratar um paciente e aparelhos e métodos para tratar terapeuticamente um paciente
NZ599246A (en) Pirfenidone therapy and inducers of cytochrome p450
IL283298A (en) Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
PH12020550978A1 (en) Use of inhaled nitric oxide and oxygen for the treatment of pulmonary hypertension
JP2015512418A5 (cg-RX-API-DMAC7.html)
PL4114466T3 (pl) Leczenie bólu i zwężenia naczyń
EP4171459A4 (en) VASOCOMPRESSION DEVICES AND METHODS FOR ADMINISTERING VASOCOMPRESSION THERAPY TO A PATIENT UNDERGOING CHEMOTHERAPY TREATMENT
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
IL285171B2 (en) Treatment of skin lesions and itching in patients with PRURIGO NODULARIS
HK40089328A (en) Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
GB202006072D0 (en) Method of selecting patients for treatment with cmbination therapy
MY200960A (en) Treatments For Heart Failure And Cardiac Ischaemic Reperfusion Injury
IL299210A (en) Combined treatment of verapamil and methotrexate for the treatment of chronic rhinosinusitis
IL300096A (en) Methods for reducing the concentration of glycosphingolipids in the brain tissue and methods for treating neurodegenerative diseases associated with it
RS67158B1 (sr) 1-metil-1h-pirazol-3-il derivati za upotrebu u lečenju neovaskularnih bolesti
JP2016504361A5 (cg-RX-API-DMAC7.html)
CN209713621U (zh) 一种轨道式腹部按摩器
IL327395A (en) Use of ALVELESTAT in specific patients
PL4255406T3 (pl) Kwas (2s)-2-aminopentanotiowy do zastosowania jako lek oraz w terapii stwardnienia zanikowego bocznego
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
HK40084705A (en) Vasocompression devices and methods of delivering vasocompression therapy to a patient undergoing chemotherapy treatment
RU2006114547A (ru) Средство и способ лечения фетоплацентарной недостаточности
GB202106014D0 (en) Use of inhaled interferon-beta to improve outcome in SARS-CoV-2 infected patients

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)